Association between the use of female hormones and the thrombin generation: Cross-sectional analysis of the Longitudinal Study on Adult Health (ELSA-Brasil)
Keywords:Contraceptives, Oral; Hormone Replacement Therapy; Blood coagulation tests.
Introduction: The thrombin generation assay (TGA) assesses the risk of developing thrombotic events. The aim of this study was to investigate the association between the use of oral contraceptives (OCs) and hormone therapy (HT) with the TGA and resistance to activated protein C (APC). Methods: Cross-sectional study with women from the Longitudinal Study of Adult Health (ELSA-Brasil). TGA was performed by the CAT method. Results: There was an association between all parameters of the TGA and the use of OCs and an association of lag time and peak time with the use of HT. Conclusion: The TGA allows us to assess the hypercoagulability status and may be useful in the management of female hormones users.
Alhenc-gelas, M., et al. (2004). Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. Journal of Thrombosis and Haemostasis, 2: 1594–1600.
Aquino, E. M., et al (2021). Brazilian Longitudinal Study of Adult Health (ELSA-Brasil): objectives and design. Am J Epidemiol, 4, 315-24.
Arruda, V. R., et al. (1995). Factor V Leiden (FVQ 506) is common in a Brazilian population. American Journal of Hematology, 49:242-243.
Brummel-Ziedins, K. E., & Wolberg, A. S. (2014). Global assays of hemostasis. Curr Opin Hematol, 21(5):395–403.
Canonico, M., et al. (2010). Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause: The Journal of The North American Menopause Society. 17, 1122/1127.
CLSI, 2007. Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture; approved standard-sixth edition. CLSI Document H3-A6, Wayne (PA): CLSI.
Compiled by Earth Policy Institute from U.N. Population Division. World Contraceptive Use 2011, wall chart (2011) .www.google.fr/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CCMQFjAA&url=http%3A%2F%2Fwww.earthpolicy.org%2Fdatacenter%2Fxls%2Fhighlights26_all.xls&ei=FZ0WVKPMOdTvaKXzgqgP&usg=AFQjCNF10wNQtG2aoPUgkK9YRymHRxb5cw&sig2=ZpqOHEY2CTVVkIA 9WUrS4Q&bvm=bv.75097201,d.d2s.
Dargaud, Y., et al. T (2007). Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study. Journal of Haematology, 139, 303–309.
Departamento de Ciência e Tecnologia do Ministério da Saúde (2009). ELSA Brasil: maior estudo epidemiológico da América Latina. Revista de Saúde Pública, v. 43, p. 1.
Glintborg, D., et al. M (2015). Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives. Metabolism Clinica and Experimenta, l6 4:1272–1278.
Grodstein, F., et al (1996). Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet, 348, 983-987.
Grodstein, F., et al (1996). Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet, 348:983-7.
Grodstein, F., et al (1996). Posmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl. J. Med, 335, 453-461.
Gutthann, S. P., et al. (1997). Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ, 314:796-800.
Hannaford, P. (2000). Cardiovascular events associated with different combined oral contraceptives: a review of current data. Drug Saf. 22(5):361-71.
Heit, J. A., et al. (2016). The epidemiology of venous thromboembolisam. J Thromb Thrombolysis, 41(1):3–14.
Heit, J. A. (2005). Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost, 3, 1611–17.
Hoibraaten, E., et al. (1999). Hormone replacement therapy with estradiol and risk of venous thromboembolism: a population- based case-control study. Thromb Haemost, 82, 1218-21.
Lecut, C., et al. (2015). Is there a place for thrombin generation assay in routine clinical laboratory? Ann Biol Clin (Paris), 73(2):137–49.
Lidegaard, O., et al. (2011). Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ, 343: d6423.
Lowe, G., et al. (2000). Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45–64 years. Relationships to hormone replacement therapy. Thromb Haemost, 83, 530–5.
Macfarlane, R. G., & Biggs, R. (1953). A thrombin generation test; the application in haemophilia and thrombocytopenia. J Clin Pathol, 6(1):3–8.
Notelovitz, M., & Greig, H. B. W. (1975). The effect of natural oestrogen on coagulation. S Afr Med J, 49, 101.
Oger, E., et al (2003). Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein
C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol, 23:1671-1676.
Olivieri, O., et al (1995). Resistance to activated protein C in healthy women taking oral contraceptives. Brit J Haematol, 91: 465-70.
Organização Mundial da Saúde (2003). Anticoncepcionais Orais: o que há de novo.
Pitney, W. R., & Dacie, J. V. (1953). A simple method of studying the generation of thrombin in recalcified plasma; application in the investigation of haemophilia. J Clin Pathol, 6(1):9–14.
Roach, R. E. J., et al. (2011). The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. Journal of Thrombosis and Haemostasis, 11: 124–131.
Rosendaal, F. R., et al. (2003). Estrogens, progestogens and thrombosis. Journal of Thrombosis and Haemostasis, 1, 1371–1380.
Rosing, J., et al (1997). Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol, 97: 233-8.
Rozenberg, S., et al. (2013). Postmenopausal hormone therapy: risks and benefits. Nat Rev Endocrinol, 9,216-27.
Ruhl H, Schroder L, Muller J, Sukhitashvili S, Welz J, Kuhn WC, Oldenburg J, Rudlowski C, Potzsch B (2014). Impact of Hormone-Associated Resistance to Activated Protein C on the Thrombotic Potential of Oral Contraceptives: A Prospective Observational Study. Plos One, 9.
Scarabin, P. Y., et al. (2015). Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestogens. Menopause: The Journal of The North American Menopause Society. 18, 873/879.
Stampfer, M. J., et al. (1990). Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses' Health Study. Am J Obstet Gynecol. Jul;163(1 Pt 2):285-91.
Tchaikovski, S. N., & Rosing, J. (2010). Mechanisms of Estrogen-Induced Venous Thromboembolism. Thrombosis Research 126, 5–11.
Tripodi A (2020). Usefulness of thrombin generation. Hämostaseologie, 40: 509-514.
van Vliet, H. A., et al (2008). Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost, 6: 346–51.
Vessey, M., et al. (1986). Oral contraceptives and venous thromboembolism: findings in a large prospective study. BMJ.
Vieira, C. S., et al. (2007). Female hormones and hemostasis. Rev Bras Ginecol Obstet. 29, 538-47.
Vigo, F., et al. (2011). Progestógenos: farmacologia e uso clínico. Femina, 39
Vlieg, van H., et al. (2009). The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ, 339:b2921.
Zia, A., et al. (2015). Hypercoagulability in adolescent girls on oral contraceptivesglobal coagulation profile and estrogen receptor polymorphisms. Am. J. Hematol. 90:725–731.
How to Cite
Copyright (c) 2021 Thaís Resende Batista; Sandhi Maria Barreto; Ana Paula Ferreira Silva; Wander Valadares de Oliveira Junior; Chams Bicalho Maluf; Antônio Luiz Pinho Ribeiro; Maria das Graças Carvalho; Roberta Carvalho de Figueiredo; Danyelle Romana Alves Rios
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.